Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Type 2 diabetes mellitus into primary care – a ‘no-brainer’?

January 19th 2016

The project to move the management of patients with type 2 diabetes (T2DM) from secondary care specialists to primary care began in the 1970’s but gained major momentum over the last ten years. It is a central pillar of health policy in the UK but on what evidence is this based?

Most NHS initiatives are based on cost reduction but is this a cheaper option? As a secondary care specialist, my costs for outpatient review are modest; an office, computer, sphygmomanometer, monofilament and support staff. I presume that these are no different to primary care but that the attributed costs are higher due to a costing formula? Furthermore, if my practice is physically moved into primary care, then the numbers of patients reviewed will decrease since the SpR training grades are not be in attendance. Finally, my availability to supervise on-call and in-patient general medicine patients is reduced, needing more resource expenditure in those areas.

Has the increase in primary care management of T2DM led to improvements in outcomes? It seems not, in terms of the surrogate marker of HbA1c, which remains stubbornly unchanged. Furthermore, ‘treatment inertia’ indicating slow escalation of pharmacotherapy including oral medication and insulin is reported to be worse in the UK than in most developed economies. This is not a criticism of general practitioner colleagues. There are currently eight different classes of anti-diabetic medications available in the UK with over thirty commonly used insulin preparations, three of which have been licenced for use in the last twelve months. As a specialist who focusses on diabetes, I struggle to keep up-to-date; why would anyone expect a generalist practitioner and supporting practice nurse to have this specialist knowledge?

The major push for a primary care takeover of T2DM is the massive numbers of people with the condition. Surely this has to be the focus? We need measures to reverse the epidemic and clever means (involving information technology) to allow specialist management of people with this complex disease.

Professor Steve Bain

Categories: Updates

Diabetes Updates Archive

calendar-iconDiabetes Updates Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

Boehringer IngelheimAstraZenecaNovo NordiskNapp Diabetes

Silver Sponsors

About Ascensia Diabetes CareAbbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership